SAR302503 (TG101348)

DRUG2 trials

Sponsors

Bristol-Myers Squibb

Conditions

MyelofibrosisNeoplasm Malignant

Phase 1

A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis

CompletedNCT00724334

Bristol-Myers SquibbMyelofibrosis

Start: 2008-07-31End: 2014-05-31Updated: 2025-03-05

Effect of SAR302503 on ECG Activity in Patients With Solid Tumors

CompletedNCT01836705

Bristol-Myers SquibbNeoplasm Malignant

Start: 2013-05-31End: 2014-05-31Updated: 2025-03-05

Related Papers

Effect Of Treatment With The JAK2-Selective Inhibitor Fedratinib (SAR302503) On Bone Marrow Histology In Patients With Myeloproliferative Neoplasms With Myelofibrosis

Blood2013-11-157 citations